Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.49 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | MB | P02144 | 1/20 | 0.48 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.48 |
| ▸ | CA3 | P07451 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15047897 | 0.82 | SMN1; SMN2 (0.57) | MEN1KMT2AHTTLMNAALDH1A1 | |
| SCHEMBL11235456 | 0.80 | SMN1; SMN2 (0.55) | MEN1KMT2AHTTLMNAALDH1A1 | |
| SCHEMBL14835973 | 0.79 | MEN1 (0.67) | MEN1KMT2AHTTLMNAALDH1A1 | |
| SCHEMBL6209273 | 0.79 | LMNA (0.54) | MEN1KMT2AHTTLMNAALDH1A1 | |
| SCHEMBL10815283 | 0.79 | SMN1; SMN2 (0.53) | MEN1KMT2AHTTLMNAALDH1A1 | |
| SCHEMBL9821071 | 0.79 | SMN1; SMN2 (0.53) | MEN1KMT2AHTTLMNAALDH1A1 | |
| SCHEMBL15598698 | 0.79 | SMN1; SMN2 (0.53) | MEN1KMT2AHTTLMNAALDH1A1 | |
| SCHEMBL4051682 | 0.79 | ALDH1A1 (0.56) | MEN1KMT2AHTTLMNAALDH1A1 | |
| SCHEMBL10701976 | 0.77 | SMN1; SMN2 (0.52) | MEN1KMT2AHTTLMNAALDH1A1 | |
| SCHEMBL10956775 | 0.77 | ALDH1A1 (0.56) | MEN1KMT2AHTTLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579352-B2 | Retinoic acid mimetic anilides | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-08-25 | — | — | US | disclosed |
| US-20080058334-A1 | Retinoic Acid Mimetic Anilides | MABIRE DOMINIQUE | 2008-03-06 | — | — | US | disclosed |
| US-20070105858-A1 | RETINOIC ACID MIMETIC ANILIDES | MABIRE DOMINIQUE | 2007-05-10 | — | — | US | disclosed |
| US-7179825-B2 | Retinoic acid mimetic anilides | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-20 | — | — | US | disclosed |
| US-6936626-B2 | Retinoic acid mimetic anilides | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-08-30 | — | — | US | disclosed |
| US-20050165018-A1 | Retinoic acid mimetic anilides | MABIRE DOMINIQUE (FR) | 2005-07-28 | — | — | US | disclosed |
| EP-1037880-B1 | RETINOIC ACID MIMETIC ANILIDES | JANSSEN PHARMACEUTICA NV (BE) | 2004-06-30 | — | — | EP | disclosed |
| US-20020115653-A1 | Retinoic acid mimetic anilides | MABIRE DOMINIQUE (FR) | 2002-08-22 | — | — | US | disclosed |
| US-6319939-B1 | P-(HETEROCYCLIC METHYL)-SUBSTUTED ANILIDES ARE POTENT INHIBITORS OF THE RETINOIC ACID METABOLISM | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-11-20 | — | — | US | disclosed |
| EP-1037880-A1 | RETINOIC ACID MIMETIC ANILIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-09-27 | — | — | EP | disclosed |
| WO-1999029674-A1 | RETINOIC ACID MIMETIC ANILIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115653-A1 | Retinoic acid mimetic anilides | RXRA, RXRB, RXRG | MEN1 4443/4885KMT2A 2932/4885HTT 2464/4885 |
| US-20050165018-A1 | Retinoic acid mimetic anilides | RXRA, RXRB, RXRG | MEN1 3649/4885KMT2A 3958/4885HTT 2246/4885 |
| US-20080058334-A1 | Retinoic Acid Mimetic Anilides | RXRA, RXRB, RXRG | MEN1 3705/4885KMT2A 3811/4885HTT 2206/4885 |
| US-20070105858-A1 | RETINOIC ACID MIMETIC ANILIDES | RXRA, RXRB, RXRG | MEN1 3649/4885KMT2A 3958/4885HTT 2246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.